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Innate and adaptive immunity contribute to the pathogenesis of autoimmune arthritis by generating and maintaining
inflammation, which leads to tissue damage. Current biological therapies target innate immunity, eminently by interfering
with single pro-inflammatory cytokine pathways. This approach has shown excellent efficacy in a good proportion of patients
with Rheumatoid Arthritis (RA), but is limited by cost and side effects. Adaptive immunity, particularly T cells with a regulatory
function, plays a fundamental role in controlling inflammation in physiologic conditions. A growing body of evidence suggests
that modulation of T cell function is impaired in autoimmunity. Restoration of such function could be of significant therapeutic
value. We have recently demonstrated that epitope-specific therapy can restore modulation of T cell function in RA patients.
Here, we tested the hypothesis that a combination of anti-cytokine and epitope-specific immunotherapy may facilitate the
control of autoimmune inflammation by generating active T cell regulation. This novel combination of mucosal tolerization to
a pathogenic T cell epitope and single low dose anti-TNFa was as therapeutically effective as full dose anti-TNFa treatment.
Analysis of the underlying immunological mechanisms showed induction of T cell immune deviation.
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INTRODUCTION
Much progress has recently been achieved on our knowledge of
the immunological and molecular mechanisms, which lead to
amplification, and perpetuation of autoimmune inflammation.
This progress has been translated into a generation of biologic
therapeutic agents that target pro-inflammatory cytokines, with
the aim of interfering with their mechanism of action. This
approach is destined to progressively complement and, in some
cases, replace currently used immunosuppressive and anti-
inflammatory therapies. Despite their success[1,2], current anti-
cytokine approaches remain hampered with limitations associated
eminently with generalized immunosuppression and subsequent
increased occurrence of malignancies and infectious diseases, in
particular tuberculosis[3–6].
Conceptually, therapeutic intervention focused on modulation of
T cell function leads to the promise of higher specificity and lower
toxicity[7–16]. This objective has for long remained a challenge in
humans, particularly due to the difficulty of identifying means of
intervention that could affect T cell function in a specific fashion.
In a Phase I/IIa trial, we have recently described immunological
effects of epitope specific immunotherapy in a group of patients with
rheumatoid arthritis. The epitope employed was derived from the
heat shock protein (HSP) dnaJ. We have proposed a central role
for HSP-specific T cell responses in the physiologic mechanisms
of modulation of inflammation[17–20]. We have also suggested
impairment of such modulation as one of the mechanisms of
amplification of autoimmune inflammation[21–24]. Our treatment
sought to restore such control by inducing mucosal tolerization to
a peptide with a potential pathogenic, not necessarily etiologic
role[25]. Immunological effects of the treatment consisted of
immunodeviation from pro-inflammatory to tolerogenic type T cell
responses to the peptide employed in the treatment. Restoration of
regulatory T cell activity was also observed.
Effects of anti cytokine therapy on T cell function, both effector
and regulatory, have been suggested[13,26–28]. These interac-
tions are relevant for many different reasons, including ultimately
the design of an optimal biologic therapy based on the com-
bination of anti-cytokine and T cell epitope specific approaches.
The work presented here lays the foundation for this strategy by
exploring clinical and immunological effects of the combination of
epitope specific T cell and anti-cytokine therapy. We employed for
this purpose Adjuvant Arthritis (AA). This is an experimental form
of arthritis that is T cell dependent and can be passively
transferred by a T cell clone that is specific for the 180-188
amino acid sequence of mycobacterial HSP60[29,30]. In previous
studies we showed that nasal administration of a 15-mer peptide
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tolerance[31] and can prevent AA. Treatment with nasal
administration of peptide 180-188 after the induction of AA is
mildly effective. Here, we compared immunological and clinical
effects of different dose regimens, namely full dose anti-TNFa,
which is known to be effective[32], mucosal tolerization to the
peptide alone, anti-TNFa at one third of the effective dose, and the
combination of low dose anti-TNFa and epitope specific therapy.
We found that the combination of low dose anti-TNFa
associated with mucosal tolerization to the arthritogenic T cell
epitope led to a significant reduction of arthritis clinically as well as
histologically, to a degree entirely comparable with what was
achieved with full dose anti-TNFa. Interestingly, treatment
regimens differed for their influence on immune responses.
Indeed, combination therapy induced T cells with a regulatory
phenotype, consisting of CD4+CD25+ cells producing IL-10 and
expressing FOXP3. Combination treatment also induced immune
deviation in CD4+CD252 cells, which were found producing
IL-10, as well as IL-4. Such changes were not present in the full
dose anti-TNFa therapy group.
Our data provide a compelling rationale for testing the
combination of anti-cytokine and epitope specific immunotherapy
in human autoimmune disease.
METHODS
Animals
Male inbred Lewis rats (RT1B) were obtained from Harlan
(Indianapolis). Rats were 6–9 weeks old at the start of each
experiment.
Antigens and adjuvants
Heat killed Mycobacterium tuberculosis (Mt, strain H37Ra) was
obtained from Difco (Detroit, MI). Incomplete Freund’s Adjuvant
(IFA; Difco, Detroit, MI) was used as adjuvant. The peptide used
in this study was prepared in large quantities by standard solid
phase Fmoc chemistry. It was obtained as COOH terminal amide
and was analyzed and purified by reverse-phase HPLC. The
following peptide was used: Mycobacterium tuberculosis HSP60 180-
188, containing Mycobacterium tuberculosis HSP60 sequence 180-188
(TFGLQLELT). 180-188 is recognized by the arthritogenic T cell
clone A2b and is a dominant T cell epitope found after Adjuvant
Arthritis (AA) and after immunization with mycobacterial
HSP60.
Induction and Clinical Assessment of Experimental
Arthritis
Rats were lightly anesthetized using isoflurane and AA was
induced by a single intradermal (i.d.) injection in the base of the
tail with 0.1 mg Mycobacterium tuberculosis (Mt) suspended in 100 ml
of IFA (Complete Freund’s Adjuvant; CFA). Rats were examined
daily for clinical signs of arthritis in a blinded set-up. Severity of
arthritis was assessed by scoring each paw from zero to four based
on degree of swelling, erythema and deformation of the joints.
Thus the maximum score was 16. On day 23 after the induction of
arthritis the rats were sacrificed by CO2 inhalation, after which
mandibular lymphnodes (MLN), Inguinal Lymphnodes (ILN),
spleen and hind limb joints were collected.
Immunotherapy Protocols
Rats were lightly anesthetized using metofane for all nasal
treatments or isoflurane for all subcutaneous treatments. Etaner-
cept (EnbrelH, Wyeth) was administered subcutaneously (s.c.) at
a concentration of 0.3 mg/kg per rat dissolved in 100 ml PBS
using a 25-gauge needle. This was done on day 9 after the
induction of arthritis with Mt. Some rats in control groups
received additional Etanercept on day 11 and 13. 100 mgo f
peptide dissolved in PBS was administered nasally in a total
volume of 10 ml( 5ml per nostril, peptide concentration 10 mg/ml)
using a micropipette. This was done on day 10, 13, 16, 19 after
arthritis induction with Mt.
Adoptive transfer
MLN, ILN and spleen of 2–3 rats per group after combination
treatment with Etanercept and 180-188 were harvested on day 23
after the induction of arthritis. Cells were cultured in vitro with
2.5 mg/ml conA for 48 hours. Subsequently, 13610
6 MLN,
11610
6 ILN and 11610
6 spleen cells were injected i.v. into the
tail vein of rats one week after induction of arthritis with Mt. Rats
were subsequently examined daily for clinical signs of arthritis in
a blinded set-up as described previously.
Histological assessment of hind limb joints
Hind limb joints were collected on day 23 after the induction of
arthritis, after the rats were sacrificed by CO2 inhalation.
Formalin-fixed tissues were decalcified, and glass slides stained
with H&E and Safranin O (for cartilage) were prepared and
evaluated by standard methodology (Comparative Biosciences,
Inc.). The pathologist examined all of the submitted tissue sections
in a blinded fashion by light microscopy and scored for
inflammation of the synovium, pannus formation, cartilage
damage, inflammation of the bone marrow and periostal pro-
liferation. Each of these parameters was scored for 10 days,
severity from 0 (normal) to 4 (severe). A cumulative score was
given based upon the sum of all of the parameters measured.
Intracellular Cytokine Staining
MLN cells were cultured for 72 hours with medium alone or
antigen. During the last 4 hours of culture 1 M monensin
(GolgiStopH, Pharmingen, San Diego, CA) was added. Viable
cells were harvested and washed with FACS blocking buffer (PBS
with 10% FBS) and 0.03% 1 M sodium azide) and subsequently
stained for 30 minutes on ice in 100 ml of blocking buffer with the
following conjugated monoclonal antibodies for extracellular
antigens: PE, FITC or CY-conjugated anti-rat CD4 (clone OX-
35, mouse IgG2a), FITC-conjugated anti-rat CD25 (clone OX-39,
mouse IgG1) (BD Pharmingen, San Diego CA). The cells were
washed twice in staining buffer (PBS containing 3% FBS and
0.03% 1 M sodium azide) and resuspended in 100 ml fixation
buffer (Cytofix/CytopermH, BD Pharmingen, San Diego, CA) for
20 minutes on ice. The cells were washed twice in permeabiliza-
tion buffer (Perm/WashH, Pharmingen, San Diego CA) and
resuspended in 100 ml permeabilization buffer and stained with
the following conjugated monoclonal antibodies: PE-conjugated
anti-rat IL-4 (clone OX-81, mouse IgG1), PE-conjugated anti-rat
IL-10 (clone A5-4, mouse IgG2b), PE-conjugated anti-rat TNFa
(clone TN3.-19.12, hamster IgG) and PE-conjugated anti-mouse
CTLA-4 (anti CD152) (clone UC10-4F10-11, armenian hamster
IgG, group 1k) (all antibodies from Pharmingen, San Diego, CA).
The appropriate isotype controls were used. Finally, the cells were
washed twice, resuspended in staining buffer, and transferred to
FACS tubes for analysis. Stained cells were analyzed on a FACStar
Plus cytometer (Becton and Dickinson). At least 5.000 events were
acquired from each sample and subsequently analyzed with Lysis
II software.
Epitope Specific Immunotherapy
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magnetic bead separation
MLN were incubated for 15 hours with medium or antigen.
Viable cells were harvested and first the cell suspensions were
depleted of monocytes, phagocytes, NK cells and B cells by
magnetic bead separation using the CELLectionHBiotin Binder kit
(Dynal A.S. Oslo, Norway). In brief, cells were incubated with the
following monoclonal antibodies: biotin mouse anti rat mono-
nuclear phagocyte, (C17, Pharmingen), biotin mouse anti rat
CD161a (10/78, Pharmingen) and biotin mouse anti rat CD45RA
(OX-33, Caltag Laboratories). Positive selection was performed
using streptavidin coated magnetic Dynabeads using the Dynal
Magnetic Particle Concentrator.
The thus obtained cells were washed in FACS blocking buffer
and stained extracellularly with anti rat CD4 and anti rat CD25.
Subsequently, cells were sorted by FACS (FACS Vantage, Beckton
Dickinson San Jose, CA) into CD4+CD25+ and CD4+CD252
cells.
Real Time Quantitative PCR (Taqman)
MLN were incubated for 15 hours with medium or antigen. Cells
were sorted into CD4+CD25+ cells and CD4+CD252 cells as
described above, resuspended in Lysis buffer (Qiagen,Valencia,
CA) and frozen at 280uC until analysis. mRNA was extracted
from sorted cells by using RNeasy Mini Kit (Qiagen). mRNA was
then reverse-transcribed into cDNA with an oligo dT primer
(Oligo(dT)12-18, Invitrogen). Subsequently, single stranded cDNA
was amplified with the cytokine specific forward and reverse
primer sets for GAPDH (housekeeping gene), IL-10, TNFa and
FOXP3. mRNA levels were determined by Real Time Quanti-
tative PCR on an ABI PRISMH 7000 thermal cycler (Perkin
Elmer). The following combinations of primers and probes were
used: IL-10 Forward 59GCC TGG CTC AGC ACT GCT AT 39,
IL-10 Reverse 59CGG ATG GAA TGG CCT TTG 39, IL-10
Probe-FAM 59 TTG CCT GCT CTT ACT GGC TGG AGT
GAA 39. TNFa Forward 59ACA AGG CTG CCC CGA CTA C
39, TNFa Reverse 59TCC TGG TAT GAA ATG GCA AAC C
39, TNFa Probe-JOE 59TGC TCC TCA CCC ACA CCG TCA
GC 39. FOXP3 Forward 59CCA TTG GTT CAC ACG CAT
GT 39, FOXP3 Reverse 59TGG CGG ATG GCA TTC TTC 39,
FOXP3 Probe-JOE 59CGC CTA CTT CAG AAA CCA CCC 39.
GAPDH Forward 59TGA CTC TAC CCA CGG CAA GTT 39,
GAPDH Reverse 59TTC CCG TTG ATG ACC AGC TT 39,
GAPDH Probe-FAM 59ACG GCA CAG TCA AGG CTG AGA
ATG G 39.
To quantify the amount of mRNA for the different target genes
the standard curve method was used[33].The relative amounts of
target gene and GAPDH were quantified by a linear extrapolation
of the Ct values using the equation to the line obtained from the
standard curve of the respective target genes. Data were
normalized for target gene expression, which was obtained by
dividing the relative quantity of target gene for each sample
divided by the relative quantity of GAPDH for the same sample.
The final read outs are expressed as induction index (arbitrary
units) defined as stimulated subtracted by reference condition, i.e.
only media culture.
Statistical analysis
A two tailed, paired t-test was performed to compare clinical
scores on day 23 and to compare Area under the arthritis score
curve. Kolmogorov-Smirnov Statistics were applied for statistical
analysis of FACS histograms.
RESULTS
Combination of epitope specific therapy and a single
low dose of Etanercept (EnbrelH) has clinical efficacy
comparable to full dose Etanercept in controlling
Adjuvant Arthritis
Lewis rats were immunized with 100 mg Mt to induce AA and
randomly divided into 5 treatment groups: i) no treatment; ii) three
doses of Etanercept s.c., equivalent in this model to a full course of
Etanercept treatment; iii) one dose of Etanercept s.c.; iv) four nasal
administrations of HSP60 peptide 180-188 v) combination of one
dose of Etanercept s.c. followed by four nasal treatments with
HSP60 peptide 180-188. Three independent experiments were
performed, with 6 rats per treatment group. The lowest effective
dose of Etanercept was determined in preliminary experiments
(not shown). Two different parameters were employed to measure
clinical outcomes, in order to ascertain full evaluation of the effects
of the various treatment regimens: i) mean arthritis scores on day
23 (the day of maximum arthritis severity); ii) area under the curve
of the corresponding arthritis score curves, thus taking into
consideration the whole time course of the treatment.
A significant reduction of AA mean arthritis scores on day 23
(p=0.0004) was achieved with epitope specific and low single dose
Etanercept combination treatment as well as with a full course of
Etanercept therapy (p=0.004) compared to no treatment.
Similarly, when assessing the areas under the curve (AUC) of
the corresponding arthritis score curves, a significant decrease of
AA was seen after epitope specific and low single dose Etanercept
combination treatment (p=0.02 vs. no treatment). Comparable
disease control was achieved in the full dose Etanercept treatment
group (p=0.03 vs. no treatment).
One dose of Etanercept alone on day 9 was able to suppress
arthritis only temporarily; however, as expected, after day 17 the
arthritis revived (Day 23 p=0.3, AUC p=0.1 vs. no treatment).
Treatment with HSP60 peptide 180-188 alone showed a trend
towards reduction of arthritis, without achievement of statistically
significant differences (Day 23 p=0.07, AUC p=0.26 vs. no
treatment). Combination of treatment with an irrelevant peptide,
derived from Ovalbumin, and low dose Etanercept lacked efficacy
in suppressing arthritis, thus confirming the epitope specificity of
the treatment (Figure 1 and Table 1).
Hence, regardless of the outcome parameter employed,
combination of epitope specific and low single dose Etanercept
therapy enabled complete clinical control of the arthritic process to
a degree statistically comparable with full dose Etanercept,
a therapeutic regimen known to fully control AA.
Epitope specific and low single dose Etanercept
combination therapy leads to a decrease of damage
in the hind limb joints
Next we investigated if clinical control of AA with combination
therapy was matched in the same treatment groups by
a corresponding decrease in joint destruction by the arthritic
process. Hind limb joints were collected on day 23 after the
induction of arthritis and scored for severity of inflammation in the
synovium, pannus formation, cartilage damage, inflammation of
the bone marrow and periostal proliferation, with a maximum
total score of 20.
Epitope specific and single low dose Etanercept combination
therapy led to a significant improvement of the histological score
in the joints (p=0.014 vs. untreated). Similarly, full course of anti-
TNFa therapy led to a significant decrease of histological damage
Epitope Specific Immunotherapy
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to significant improvement (p=0.214) (Figure 2).
Epitope specific and single low dose Etanercept
combination therapy induces immune deviation of
CD4+ T cells
We then analyzed the immune mechanism responsible for the
clinical effects of the treatments tested. We focused in this part of
our analysis on defining qualitatively CD4+ mediated T cell
responses to the inciting antigen. The rationale behind this
strategy was to identify qualitative changes in cytokine responses
induced by the treatment. To this end, we measured cytokine
production and surface marker expression of CD4+ T cells present
in the Mandibular Lymphnodes (MLN), the draining site of the
nasal mucosa where T cell immune deviation may be induced.
MLN were isolated on day 23 after arthritis induction and
cultured with HSP60 peptide 180-188 or media. It has to be noted
that HSP60 peptide 180-188 is the major immune dominant
epitope following induction of AA (due to the presence of
mycobacterial HSP65 in CFA) and thus can act as an important
surrogate parameter for (immune) therapy in AA[34,35]. After
72 hours viable cells were harvested and stained for surface
markers and intracellular cytokines and analyzed by FACS. The
results showed differences between treatment groups in the
immune mechanisms underlying sometimes comparable clinical
efficacy. In fact, only the epitope specific/low dose Etanercept
combination treatment group showed clear indication of T cell
immune deviation, as indicated by the significant difference
compared to the untreated group as well as the Etanercept groups
in the increased production of IL-10 regulatory cytokine (MFI
11.84, isotype control 7.69, p,0.001). Expression of CTLA-4,
a marker of T cells with regulatory function, also significantly
increased when compared both to untreated and Etanercept
groups (MFI 18.16, isotype control 7.10, p,0.001). An increase in
IL-4 production was seen after the combination treatment as well
as after the full course of Etanercept therapy (MFI 8.20 and 10.19,
isotype control 6.96, p,0.001) (Figure 3).
These data are, in our opinion, intriguing as they show
differences in underlying immunological mechanism between two
equally clinically effective treatments. Indeed, the marked
increases in IL-10 production and CTLA-4 expression following
combination therapy were both strongly suggestive of restored
modulation of T cell function.
Enhancement of CD4+CD25+ regulatory T cell (Treg)
function by epitope specific/low dose anticytokine
combination therapy
In this part of the project, we addressed the questions on: i)
whether certain aspects of regulatory T cell (Treg) function were
affected by the combination therapy; ii) whether such induction
would affect immune deviation in effector T cells; iii) whether
differences in these parameters between full dose Etanercept and
epitope specific and low single dose Etanercept combination
therapy could be found.
To this end, we chose to measure by real time PCR (TaqMan)
expression of two functional markers of Treg function: IL-10 and
FOXP3. FOXP3 is a forkhead transcription factor whose
expression is deemed crucial for Treg function. IL-10 is considered
among the most important soluble mediators for regulatory T cell
function. We also measured expression of TNFa, to evaluate if the
Figure 1. Combination therapy of Etanercept with mycobacterial
heat shock protein 60 (HSP60) 180-188 led to significant reduction of
Adjuvant Arthritis (AA). Arthritis was induced on day 0 with Complete
Freund’s Adjuvant (CFA). On day 9, rats were randomly divided into five
treatment groups: three doses of Etanercept s.c. on day 9, 11, 13
(equivalent to a full course of Etanercept treatment); one dose of
Etanercept on day 9; four doses of mycobacterial HSP60 peptide 180-
188 on day 10, 13, 16, 19; combination treatment of one dose of
Etanercept s.c. on day 9 followed by 180-188 nasally on day 10, 13, 16,
19; or no treatment (PBS). Arthritis scores were assessed every other day
from day 8 onward. N=15–18 rats per treatment group. Shown are
mean arthritis scores.
doi:10.1371/journal.pone.0000087.g001
Table 1. Combination treatment as well as a full course Etanercept treatment led to significant reduction of arthritis on day 23,
when maximum score of disease is reached, as well as a significant reduction of the area under the arthritis score curve (AUC),
representative of the whole treatment period.
..................................................................................................................................................
TREATMENT GROUPS
Mean arthritis score
on day 23
Arthritis score on day 23 vs.
no treatment (p-value)
Area under the
Curve (AUC)
AUC vs. no treatment
(p-value)
Etanercept 36 5.8 0.004 42.639 0.03
Etanercept 16 8.3 n.s. 48.858 n.s.
180-88 46 7.1 n.s. 54.726 n.s.
Etanercept 16+180-188 46 4.9 0.0004 40.396 0.02
Etanercept 16+OVA 46 9.0 n.s. 79.597 n.s.
No treatment 9.8 77.748
Statistical analysis was performed by the paired t-test. Different treatment groups were set out against no treatment.
doi:10.1371/journal.pone.0000087.t001
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PLoS ONE | www.plosone.org 4 December 2006 | Issue 1 | e87Figure 2. Combination therapy as well as a full course of Etanercept treatment led to reduction of histological damage in the ankle joints. Joints
were harvested on day 23 after the induction of arthritis. Formalin-fixed tissues were decalcified, and glass slides stained with H&E were prepared.
Submitted tissue sections were examined by light microscopy and scored for severity of inflammation of the synovium, pannus formation, cartilage
damage, bone marrow inflammation and periostal proliferation, with a maximum score of 4 per parameter. N=3–4 per treatment group. H&E
staining is shown of one rat per treatment, representative for the whole treatment group. A: Combination therapy; B: Etanercept 16; C: Peptide Mt.
180-188 46monotherapy; D: No treatment; E: Etanercept 36.
doi:10.1371/journal.pone.0000087.g002
Figure 3. The combination therapy of Etanercept and HSP60 180-188 led to an antigen specific increase of IL-10 and IL-4 production and up
regulation of CTLA-4 expression in CD4+ T cells in draining Mandibular Lymphnodes (MLN). MLN were harvested on day 23 after the induction of
arthritis. Cells were cultured for 72 hours with medium or antigen. Intracellular production of IL-4, IL-10, and expression of CTLA-4 were measured by
FACS. Depicted are Mean Fluorescence Indexes (MFI) of MLN cells cultured with mycobacterial HSP60 peptide 180-188, of cells gated on CD4. Results
are representative of one experiment.
doi:10.1371/journal.pone.0000087.g003
Epitope Specific Immunotherapy
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inflammatory response of effector CD4+CD252 cells.
CD4+CD25+ cells were studied, a category of Treg that
appears functionally impaired in RA and whose efficiency might
not be entirely restored by full dose anti-TNFa treatment [26].
CD4+CD25+ and CD4+CD252 MLN cells were isolated on day
23 after arthritis induction and cultured with HSP60 peptide 180-
188 or media. After 15 hours viable cells were harvested, stained
for CD4 and CD25 and sorted by FACS. Subsequently mRNA
was extracted from sorted CD4+CD25+ and CD4+CD252 cells
and levels of FOXP3, IL-10 and TNFa measured by Real Time
Quantitative PCR. Figure 4 shows the ratio of the induction index
(cytokine/transcription factor divided by housekeeping gene
GAPDH) of stimulation with HSP60 peptide 180-188 less the
background value.
When FOXP3 expression was measured, a significant increase
was found both in the combination and full dose anti-TNFa
groups, underscoring likely effects of both therapeutic regimens on
some Treg functions, in accordance with recent findings in
Rheumatoid Arthritis patients[26]. Cytokine mediated Treg
function however might reportedly not be affected by anti-TNFa
therapy, and indeed, when IL-10 expression by CD4+CD25+ cells
was measured there was a significant increase (p=0.002) only in
the combination therapy group. Interestingly, combination
therapy and, to a lesser degree, full dose Etanercept, also induced
immune deviation of CD4+CD252 effector cells, with higher
production of IL-10 consistent with what shown in the FACS
analysis. As expected, FOXP3 expression was not induced in
CD4+CD252 cells and TNFa expression was abolished by the
combination treatment as well as by full dose Etanercept.
These data provide evidence for enhancement of Treg function
by epitope specific and low dose Etanercept combination therapy.
Enhanced or restored function of Treg led to immune deviation in
effector CD4 cells, with production of IL-10. These immunolog-
ical changes correlated with the changes in the clinical picture
induced by the treatment.
Adoptive Transfer of MLN T cells obtained from
animals treated with epitope specific/low dose
Etanercept combination therapy was able to treat
full blown autoimmune arthritis
The purpose of this experiment was to evaluate whether the effects
of the combination therapy on T cells could induce clinical
amelioration upon adoptive transfer into sick animals. We
employed T cells from spleen, Inguinal Lymphnodes (ILN) and
MLN after combination treatment with Etanercept and 180-188
on day 23 after the induction of arthritis, cultured them for
48 hours with conA and subsequently injected them i.v. into the
tail vein of rats one week after arthritis induction with Mt.
Interestingly, only T cells derived from MLN of animals treated
with the combination therapy were able to significantly reduce
(p=0.0305) clinical symptoms measured as mean arthritis score,
when transferred into animals in which disease had been induced
(Figure 5-A). Spleen cells from animals treated with combination
therapy transferred to diseased animals failed to exert an efficient
control of the disease process (Figure 5-B) as measured using percent
of clinical amelioration. ILN were able to induce a good level of
clinical amelioration (Figure 5-B), however differences with no treat-
ment control group did not reach statistical significance (Figure 5-A).
Figure 4. Combination Therapy led to an increase in FOXP3 and IL-10 gene transcription in CD4+CD25+ cells, whereas it also led to and increase
in IL-10 transcription in CD4+CD252 cells. TNFa transcription was abolished by the combination therapy as well as by a full course of
Etanercept treatment. Results are expressed as the induction index (marker/housekeeping gene GAPDH) of HSP60 peptide 180-188 stimulation
subtracted by media alone as measured by Real Time Quantitative PCR. IL-10 production Combination therapy vs. Etanercept treatment p=0.002.
N=2–4 per treatment.
doi:10.1371/journal.pone.0000087.g004
Epitope Specific Immunotherapy
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a population of T cells that resides in the lymphnodes draining the
mucosa where the tolerization occurs (MLN) and to a lesser degree
ILN. The effect of the treatment on T cells is lasting enough to
allow efficient control of the disease process by adoptive transfer in
animals in which AA was induced.
DISCUSSION
Recent years have witnessed a dramatic progress in our ability to
understand mechanisms of autoimmune inflammation and to
translate such understanding into novel therapeutic approaches.
Particularly remarkable is the success of therapies aimed at
interfering with the pro-inflammatory role played by certain
cytokines, in particular TNFa. The broadening of clinical
applications employing anti-TNFa therapy has led, however, to
two interesting developments in clinical immunology, including: i)
the recognition of significant generalized immune suppression in
treated patients, with a sizable increase in onset or relapse of
certain infectious diseases and neoplasias; ii) the need to
understand in depth the effects of the treatment on the immune
system.
In fact, the effects of anti-TNFa treatment on cytokine
production and immunoregulation are still largely unknown and
sometimes contradicting. Schotte et al. described the reduction of
the number of PBMC producing the pro-inflammatory cytokines
TNFa, IFNc and IL-1 after Etanercept therapy, whereas the
number of IL-10 producing PBMC remained the same, possibly
indicating an immune suppression rather than active immunomo-
dulation due to Etanercept[27]. Sieper and colleagues on the other
hand investigated the effects of the treatment on the T cell
population and postulated that neutralization of peripheral TNFa
by Etanercept does not lead to a down regulation of the ability to
produce TNFa or IFNc by T cells, but rather to an up regulation,
possibly due to a counter regulatory mechanism[28]. Ehrenstein et
al.[26] found that Treg function in RA is impaired, and that
treatment with Infliximab, a monoclonal antibody directed against
TNFa, restored it only partially. Namely, Treg mechanisms based
on cell-to-cell contact were restored by Infliximab treatment, while
Treg mechanisms relying on soluble mediators such as IL-10
remained ineffective despite the treatment. A recent elegant study
by Valencia et al. added important insight into the role of TNFa
on T regulatory cells. They showed that CD4CD25
bright T
regulatory cells constitutively express the TNF receptor II. An
environment with high levels of circulating TNF led to up
regulation of the TNF receptor II, which down regulated both the
quantity as well as the quality of FOXP3+ T regulatory cells.
Additionally they showed that CD4CD25
bright cells of patients
with active RA expressed high levels of TNF receptor II, reduced
levels of FOXP3 and were poor suppressors, which could be
reversed by anti- TNFa treatment[13]. These studies, at times
contradicting with respect to some mechanisms, underscored that
short-term treatment with anti-TNFa may partially restore a more
tolerogenic microenvironment, which could be instrumental for
the induction of immune tolerance with epitope specific immune
therapy.
Intervention on T cell mediated adaptive immunity would be, in
theory, ideal, given the possibility of focusing the approach on one
or more possible antigens involved in the disease process, thus
sparing the patient generalized immune suppression. Progress is
therefore needed in the area of modulation, rather than
suppression, of T cells. The most important conceptual de-
velopment may, however, be the fact that the search for the one
Figure 5. Adoptive Transfer of Mandibular Lymphnode (MLN) T cells from Combination Therapy treated animals led to significant reduction of
Adjuvant Arthritis (AA) in diseased animals, measured as Mean Arthritis Score as well as percentage of Disease Amelioration.
A. Adoptive Transfer of T cells from Combination Therapy groups. Adoptive Transfer Groups received 11610
6 Inguinal Lymphnode (ILN) cells, 13610
6
MLN cells, or 11610
6 spleen cells. Data represent Mean6SD. Disease induction and scoring was performed as described in the legend to Figure 1.
B. Percentage of Clinical Amelioration for each treatment group in AA rats. The Area Under the Curve (AUC) of each individual treatment group was
used to score the Clinical Amelioration (CA) of the distinct treatment groups. AUC was calculated using the curves originated by scoring the disease
for the different treatment groups and plotted as percentage of CA with respect to the non-treated group. The non-treated group was considered as
having an average percentage of disease=100%. Formula is as follows: CA=100 - %AUC.
doi:10.1371/journal.pone.0000087.g005
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approaches targeting mechanisms of control of self-reverberating
T cell mediated inflammation. This would realistically shift the
focus from etiology to pathogenesis based immune modulation.
A considerable body of evidence, to which we contribut-
ed[21,36,37], supports the concept that peptides derived from heat
shock proteins (HSP) may play a role in amplification of
autoimmune inflammation. As ubiquitous and bacterial derived
products, HSP-derived peptides are in fact perceived as a ‘‘danger’’
signal and elicit a default pro-inflammatory physiologic response.
Such response contributes in clearing a possible pathogen invasion
but also induces, through cellular stress, increased availability of
self-HSP derived peptides. These peptides are recognized by T
cells with regulatory function. Such function is impaired in
autoimmune arthritis[17,18].
We have recently reported the results from a Phase I/IIa clinical
trial in Rheumatoid Arthritis[25]. The objective of our clinical
intervention was to restore natural mechanisms of immune
modulation by exploiting the ability of the mucosal route in
inducing tolerization to a HSP-derived peptide, which we
previously described as part of the pro-inflammatory mechanisms
of RA pathogenesis[21]. Interestingly, we were able to induce in
treated patients immune deviation from pro-inflammatory to
modulatory T cell responses, leading to significant reduction in
TNFa and IFNc production and increase in IL-10 and IL-4.
These effects were mediated via restoration of function of
CD4CD25
bright Treg, producing IL-10 and expressing
FOXP3[25].
The study reported here addresses the questions on whether
epitope specific and anti-cytokine therapy can be complementary,
and if such synergy may be advantageous in order to exploit
modulation of adaptive immunity while reducing generalized
immune suppression, costs and side effects. In order to explore the
concept, we chose AA, a T cell, HSP-dependent model of RA,
which can be treated with full dose Etanercept. We have
previously shown in AA that mucosal tolerization to the inciting
peptide leads to immune deviation[31,38].
Combination of epitope specific and anti-cytokine therapy
induced full clinical control of AA, to a degree comparable to full
dose Etanercept and significantly better than the other treatment
regimens, including low dose Etanercept or epitope specific
therapy alone. The comparable clinical efficacy achieved by
combination treatment as well as full course Etanercept was
obtained through distinctly different immune mechanisms in both
effector T cells as well as regulatory T cells.
In effector CD4 cells, the combination therapy induced immune
deviation while full dose Etanercept appeared to be eminently
suppressive. Combination therapy led to an increased production
of IL-10, which was not found in the other treatment regimens,
including full dose Etanercept. Both treatments induced suppres-
sion of TNFa production and an increase of IL-4 production,
which may indicate the presence of a T Helper 2 type tolerogenic
mechanism complementing the main effects of the therapy.
Increasing evidence is, however, shifting the focus of modulation
of adaptive immunity from effector to regulatory T cells[39–43].
Recent progress in Molecular Immunology has enabled the
identification of phenotypical and functional characteristics for
these T cells, such as co-expression of CD4, CD25 and CTLA-4,
as well as production of certain regulatory cytokines. Several
mechanisms of actions have been proposed for Treg, based either
on release of cytokines with a tolerogenic function (eminently IL-
10), or based on direct cell-to-cell contact by the use of receptors
and pathways not yet fully elucidated[7,39,44–46].
When we sought to analyze the effects of combination therapy
and full dose Etanercept therapy, it appeared evident that different
functions of regulatory T cells were affected by the two treatments.
Both treatments significantly increased the expression of the
forkhead transcription factor FOXP3, a functional marker of
Treg, which act eminently by cell-to-cell contact. A similar
observation was described in human RA by Ehrenstein et al.[26].
However, CTLA-4 expression and IL-10 production were induced
only by combination therapy regimens, and not by anti-TNFa
treatment alone, again in agreement with what was found by
Ehrenstein. Here we provide evidence that restoration of such
function can be achieved by adding epitope specific immunother-
apy to low dose Etanercept.
Undoubtedly, anti-TNFa therapy creates an environment in
which epitope specific immunomodulation can be induced more
efficiently. Further evidence for this concept was recently obtained
by Bresson et al., who showed that combination of peptide therapy
with anti CD3 enhanced the clinical improvement in experimental
diabetes compared to anti-inflammatory therapy alone, also
through the induction of CD25+FOXP3+ Tregs, as well as insulin
specific Tregs producing IL-10 and TGFb[47].
Recently, it was elegantly shown by Zanin-Zhorov et al, that
HSP60 peptides enhance CD4+CD25+ regulatory T cell function
via TLR2 signaling [48], thereby providing an additional explana-
tion for the regulatory effects observed after combination therapy.
Further underscoring the profound immunological differences
in mechanisms of action between full dose Etanercept and
combination therapy, only cells derived from MLN of animals
treated with combination therapy were able to control disease
when transferred in sick animals. Cells with regulatory properties
have been recently described as residing in the MLN [49].
This work lays the foundation for a swift translation of this novel
immunotherapeutic concept in human Rheumatoid Arthritis. The
implications, should this approach succeed, range from increasing
the range of success and utilization of epitope specific immuno-
therapy, to reducing significantly the costs and undesirable effects
of current first generation biologics.
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